BDTX News and Press, Black Diamond Therapeutics Inc. From 06/27/23

2023-06-27 13:42:36 ET Today we are diving into the world of penny stocks. This sector has a notorious reputation in the market, and rightfully so – it can be volatile and risky. However, with the right approach, a level head, and disciplined strategies, penny stocks can offer so...

2023-06-27 13:41:49 ET Wedbush has upgraded Black Diamond Therapeutics ( NASDAQ: BDTX ) to outperform from neutral after the biotech reported positive phase 1 data on lead asset BDTX-1535 for lung cancer. The firm also boosted its target price to $10 from $3 (~443% return...

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is one of today's top gainers. The company's shares are currently up 127.72% on the day to $4.19. Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tum...

2023-06-27 10:40:21 ET Black Diamond Therapeutics ( NASDAQ: BDTX ) gained ~79% in the morning hours Tuesday after the company announced early-stage data for its lead asset, BDTX-1535, from a Phase 1 trial for patients with lung cancer. Citing dose-escalation data from the tr...

2023-06-27 10:07:53 ET Gainers: Black Diamond Therapeutics ( BDTX ) +91% . Cara Therapeutics ( CARA ) +27% . Pharvaris ( PHVS ) +21% . AC Immune ( ACIU ) +11% . Immix Biopharma ( IMMX ) +6% . Losers: Adicet Bio ( ACET ...

BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR...

2023-06-21 10:07:44 ET Gainers: Ocean Biomedical ( OCEA ) +43% . PetVivo Holdings ( PETV ) +23% . Patterson Companies ( PDCO ) +14% . Zentalis Pharmaceuticals ( ZNTL ) +5% . RenovoRx ( RNXT ) +4% . Losers: uniQure ( ...

CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mu...

CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mu...

2023-05-09 08:46:45 ET Black Diamond Therapeutics press release ( NASDAQ: BDTX ): Q1 GAAP EPS of -$0.57 beats by $0.04 . Net Loss: Net loss for the first quarter of 2023 was $20.9 million, as compared to $25.5 million for the same period in 2022. Financial Guidance...